Introduction

Rheumatoid arthritis (RA) is a long-term autoimmune disease in which the immune system attacks the joints, causing chronic inflammation (Chauhan et al., 2023; Jahid et al., 2023; Venetsanopoulou et al., 2023). RA remains a major public health concern due to its prevalence, affecting roughly 0.5% to 1% of adults worldwide (Finckh et al., 2022; Jahid et al., 2023; Prasad et al., 2022; Venetsanopoulou et al., 2023). This paper examines the pathophysiology, causes, prevalence, and relevance of rheumatoid arthritis, as well as its relationship to mismedicine.

What Is It?

RA is an autoimmune disorder characterized by sustained inflammation of the synovial membrane that lines the joints (Chauhan et al., 2023; Jahid et al., 2023; Venetsanopoulou et al., 2023). It initially affects the small peripheral joints, particularly in the hands and feet, in a symmetrical pattern, before extending to larger, more proximal joints (Chauhan et al., 2023; Venetsanopoulou et al., 2023). Genetic factors account for 40% to 65% of susceptibility (Prasad et al., 2022). Environmental influences, including cigarette smoking, air pollution, occupational exposure to silica and pesticides, and disruptions in the microbiome, further shape disease risk (Chauhan et al., 2023; Jahid et al., 2023; Venetsanopoulou et al., 2023).

How Does It Develop?

RA develops due to a combination of genetic and environmental factors (Chauhan et al., 2023; Venetsanopoulou et al., 2023). The process is thought to originate in areas regularly exposed to the environment, such as the lungs, oral cavity, and gut (Alivernini et al., 2022; Chauhan et al., 2023; Finckh et al., 2022). Exposure to inhaled irritants, infections, or pollutants can alter the structure of proteins in the body (Alivernini et al., 2022; Chauhan et al., 2023; Finckh et al., 2022; Venetsanopoulou et al., 2023). These structurally altered proteins may be recognized as “foreign” by the immune system (Alivernini et al., 2022; Prasad et al., 2022). In individuals with genetic susceptibility, this misidentification is more likely to occur (Alivernini et al., 2022; Chauhan et al., 2023; Jahid et al., 2023). This leads to the production of autoantibodies, proteins that target the body’s own tissues, which may circulate in the bloodstream years before symptoms (Alivernini et al., 2022; Chauhan et al., 2023).

The Transition to Clinical Disease

Autoantibodies alone are insufficient to cause disease in some individuals, suggesting a required additional trigger to initiate the disease (Alivernini et al., 2022; Chauhan et al., 2023). This transition is thought to involve the increased production of cytokines and chemokines, which promote immune cell recruitment to the synovium (Alivernini et al., 2022; Chauhan et al., 2023). Under the influence of inflammatory molecules, cells that normally maintain the joint lining shift into sustained pro-inflammatory states (Alivernini et al., 2022; Jahid et al., 2023). This is seen in fibroblast-like synoviocytes, which invade cartilage and bone while releasing matrix-degrading enzymes (Alivernini et al., 2022; Chauhan et al., 2023). T cells and B cells accumulate within the joint, with B cells generating autoantibodies that attach to self-antigens and amplify inflammation (Alivernini et al., 2022; Chauhan et al., 2023). Cartilage degradation is driven by enzymes that break down the structural components of cartilage and compromise joint function (Alivernini et al., 2022; Chauhan et al., 2023; Jahid et al., 2023). Bone erosion occurs through osteoclast activation. Activated osteoclasts reabsorb bone, leading to irreversible joint damage (Chauhan et al., 2023; Jahid et al., 2023).

Prevalence and Relevance

RA shows geographic variation with higher prevalence in industrialized, urbanized regions, including North America and Western Europe, and lower rates in Southeast Asia, parts of sub-Saharan Africa, and rural regions (Finckh et al., 2022). Demographically, RA disproportionately affects women, who are two- to threefold more likely to develop the disease compared to men, with incidence peaking between 65 and 80 years of age, possibly linked to sex hormone changes (Chauhan et al., 2023; Finckh et al., 2022; Venetsanopoulou et al., 2023). The disease also imposes a substantial functional burden, with about 40% of individuals experiencing significant disability within a decade of diagnosis (Chauhan et al., 2023). Persistent joint pain, swelling, and prolonged morning stiffness impair daily activities and functioning, contributing to reduced quality of life and productivity, and increased lifelong healthcare costs (Finckh et al., 2022; Jahid et al., 2023). RA is also associated with increased mortality, with life expectancy reduced by approximately 3 to 12 years and mortality rates reaching up to three times that of the general population (Chauhan et al., 2023; Jahid et al., 2023). These implications reflect elements of mismedicine, which is defined as medical practices that result in harm or inefficiency (Beigi, 2019). In RA, this is evident in the absence of definitive early diagnostic tests despite a critical window for intervention (Chauhan et al., 2023; Prasad et al., 2022). Furthermore, although MRI and ultrasonography can detect early changes, they are not fully integrated into standard diagnostic criteria, delaying and increasing the risk of diagnostic error (Chauhan et al., 2023; Jahid et al., 2023).

Conclusion

Rheumatoid arthritis (RA) is a chronic, autoimmune disease characterized by synovial joint inflammation that progresses to irreversible joint destruction, functional impairment, and reduced life expectancy (Chauhan et al., 2023; Jahid et al., 2023; Venetsanopoulou et al., 2023). It develops through interactions between genetic predisposition and environmental factors (Alivernini et al., 2022; Chauhan et al., 2023; Jahid et al., 2023; Venetsanopoulou et al., 2023). Disease prevalence and burden vary geographically, disproportionately affects women, and contribute to significant socioeconomic impact (Finckh et al., 2022; Jahid et al., 2023; Venetsanopoulou et al., 2023). A major clinical limitation is the absence of reliable early diagnostic tests (Chauhan et al., 2023; Prasad et al., 2022). Further investigation into the mechanisms that drive the transition from asymptomatic autoimmunity to clinically apparent disease may enable earlier intervention and improved outcomes (Alivernini et al., 2022; Chauhan et al., 2023; Finckh et al., 2022; Venetsanopoulou et al., 2023).

Q&A

What is the clinical hallmark of Rheumatoid Arthritis and how does it progress?

RA is characterized by chronic inflammation of the synovial membrane, initially targeting the small peripheral joints of the hands and feet (Chauhan et al., 2023; Jahid et al., 2023; Venetsanopoulou et al., 2023). If left untreated, the disease progressively extends to larger, more proximal joints, leading to irreversible cartilage and bone damage, joint deformity, and significant functional impairment (Chauhan et al., 2023).

How do genetics and the environment interact to cause RA?

Genetics account for roughly 40% to 65% of disease susceptibility (Jahid et al., 2023; Prasad et al., 2022; Venetsanopoulou et al., 2023). This genetic predisposition interacts with environmental triggers, most notably cigarette smoking, air pollution, pathogens, pesticides, and the microbiome to cause the immune system to misidentify self-proteins as foreign (Chauhan et al., 2023; Finckh et al., 2022; Prasad et al., 2022; Venetsanopoulou et al., 2023).

What is the “mucosal origin” hypothesis in the development of RA?

This hypothesis suggests that immune disruption begins at mucosal surfaces like the lungs, oral cavity, or gut due to environmental exposures (Alivernini et al., 2022; Chauhan et al., 2023; Finckh et al., 2022). These exposures trigger modifications of proteins that the immune system no longer recognizes as self, leading to the production of autoantibodies years before joint symptoms appear (Alivernini et al., 2022; Chauhan et al., 2023).

What is the global impact of RA on life expectancy and physical function?

RA affects 0.5% to 1% of adults worldwide and disproportionately impacts women (Chauhan et al., 2023; Finckh et al., 2022; Venetsanopoulou et al., 2023). The disease carries a heavy burden, with approximately 40% of patients experiencing significant disability within ten years of diagnosis and an overall reduction in life expectancy of 3 to 12 years (Chauhan et al., 2023; Jahid et al., 2023).

What are the current challenges in RA diagnosis and treatment?

A major issue is the absence of a definitive early diagnostic test, which often causes patients to miss the critical “window of opportunity” for early intervention (Chauhan et al., 2023; Prasad et al., 2022).

References

Alivernini, S., Firestein, G. S., & McInnes, I. B. (2022). The pathogenesis of rheumatoid arthritis. Immunity, 55(12), 2255–2270. https://doi.org/10.1016/j.immuni.2022.11.009

Beigi, P. (2019, February 20). The Misdiagnosis Association and Research Institution (MARI). MARI. https://mariresearch.com/

Chauhan, K., Jandu, J., & Al-Dhahir, M. (2023, May 25). Rheumatoid Arthritis. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK441999/

Finckh, A., Gilbert, B., Hodkinson, B., Bae, S.-C., Thomas, R., Deane, K. D., Alpizar-Rodriguez, D., & Lauper, K. (2022). Global epidemiology of rheumatoid arthritis. Nature Reviews Rheumatology, 18(10). https://doi.org/10.1038/s41584-022-00827-y

Jahid, M., Khan, K. U., Ul-Haq, R., & Ahmed, R. S. (2023). Overview of Rheumatoid Arthritis and Scientific Understanding of the Disease. Mediterranean Journal of Rheumatology, 34(3), 284–291. https://doi.org/10.31138/mjr.20230801.oo

Prasad, P., Verma, S., Surbhi, Ganguly, N. K., Chaturvedi, V., & Mittal, S. A. (2022). Rheumatoid arthritis: advances in treatment strategies. Molecular and Cellular Biochemistry, 478(1). https://doi.org/10.1007/s11010-022-04492-3

Venetsanopoulou, A. I., Alamanos, Y., Voulgari, P. V., & Drosos, A. A. (2023). Epidemiology and Risk Factors for Rheumatoid Arthritis Development. Mediterranean Journal of Rheumatology, 34(4), 404–404. https://doi.org/10.31138/mjr.301223.eaf

 

 

 

 

Provided and edited by the members of MARI Research, Error in Medicine Foundation and MISMEDICINE Research Institute, including Enuka Saint Jacques, Gia D’Andrea, Rojina Nariman, and Dr. Pooya Beigi MD. MSc.